Patents Assigned to Compass Therapeutics LLC
-
Patent number: 11970538Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.Type: GrantFiled: May 20, 2021Date of Patent: April 30, 2024Assignee: COMPASS THERAPEUTICS LLCInventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
-
Publication number: 20240002525Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.Type: ApplicationFiled: May 25, 2023Publication date: January 4, 2024Applicant: Compass Therapeutics LLCInventors: Ugur Eskiocak, Robert V. Tighe, III
-
Patent number: 11851497Abstract: The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.Type: GrantFiled: November 20, 2018Date of Patent: December 26, 2023Assignee: COMPASS THERAPEUTICS LLCInventors: Robert V. Tighe, III, Ugur Eskiocak
-
Patent number: 11752207Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: June 8, 2020Date of Patent: September 12, 2023Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Patent number: 11718679Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.Type: GrantFiled: October 31, 2018Date of Patent: August 8, 2023Assignee: Compass Therapeutics LLCInventors: Ugur Eskiocak, Robert V. Tighe, III
-
Patent number: 11046769Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.Type: GrantFiled: November 13, 2019Date of Patent: June 29, 2021Assignee: COMPASS THERAPEUTICS LLCInventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
-
Patent number: 10716851Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: September 6, 2018Date of Patent: July 21, 2020Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Publication number: 20200109195Abstract: The present disclosure provides immunotherapeutic compositions and methods for enhancing an immune response and for treating cancer or inflammatory conditions mediated by autoreactive B cells in a subject. In some aspects, multispecific antigen-binding constructs are provided that recognize at least one tumor antigen or B-lineage cell antigen and NKp30 and/or another activating NK receptor. In some aspects, multispecific antigen-binding constructs are provided that recognize at least two tumor antigens or two antigens expressed by B-lineage cells, NKp30, and another activating NK receptor. The multispecific antigen-binding constructs and methods disclosed herein can be used for the treatment of cancer, even a cancer characterized by a CD16 deficient microenvironment and/or characterized by target cells (e.g., cancer cells) having a low level of expression of the tumor antigen.Type: ApplicationFiled: May 21, 2019Publication date: April 9, 2020Applicant: COMPASS THERAPEUTICS LLCInventors: Jennifer Watkins, Michael March Schmidt, Monia Draghi, Amanda Frank Oliphant, Sara Marie Halmos, Thomas Joseph Schuetz, Jason Michael Lajoie, Allison Nelson
-
Publication number: 20200079867Abstract: The present disclosure provides immunotherapeutic compositions and methods for enhancing an immune response and for treating cancer or inflammatory conditions mediated by autoreactive B cells in a subject. In some aspects, multispecific antigen-binding constructs are provided that recognize at least one tumor antigen or B-lineage cell antigen and NKp30 and/or another activating NK receptor. In some aspects, multispecific antigen-binding constructs are provided that recognize at least two tumor antigens or two antigens expressed by B-lineage cells, NKp30, and another activating NK receptor. The multispecific antigen-binding constructs and methods disclosed herein can be used for the treatment of cancer, even a cancer characterized by a CD16 deficient microenvironment and/or characterized by target cells (e.g., cancer cells) having a low level of expression of the tumor antigen.Type: ApplicationFiled: September 26, 2019Publication date: March 12, 2020Applicant: COMPASS THERAPEUTICS LLCInventors: Jennifer Watkins, Michael March Schmidt, Monia Draghi, Amanda Frank Oliphant, Sara Marie Halmos, Thomas Joseph Schuetz, Jason Michael Lajoie, Allison Nelson
-
Patent number: 10434175Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: May 23, 2019Date of Patent: October 8, 2019Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Patent number: 10350292Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: April 3, 2019Date of Patent: July 16, 2019Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Patent number: 10279038Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: November 9, 2018Date of Patent: May 7, 2019Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Patent number: 10279040Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: December 21, 2018Date of Patent: May 7, 2019Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
-
Patent number: 10279039Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: December 13, 2018Date of Patent: May 7, 2019Assignee: Compass Therapeutics LLCInventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak